. Author manuscript; available in PMC: 2013 Jun 3.

Published in final edited form as: Curr Cancer Drug Targets. 2011 Jul;11(6):734–751. doi: 10.2174/156800911796191024

Table 1.

MDSC suppressor mechanisms

Mechanism	Suppressor cell phenotype	Model	Refs.
ROS release	CD11b, GR-1 CD11b, Ly6G⁺Ly6C^lo CD15 CD11b,GR-1	7 different tumor models (mice) 10 different tumor models (mice) Advanced cancer (human) CT26 colon, C-3 sarcoma (mice)	[96] [87] [59] [123]
Peroxynitrite release	CD11b, GR-1	EL4 (mice)	[124]
Arginase 1 release	CD11b, GR-1 CD11b, CD66b CD11b,GR-1,IL-4Rα CD11b,CD15	3LL (mice), NSCLC (human) RCC (human) 5 different tumor models (mice) RCC (human)	[126] [58] [65] [57]
iNOS release	CD11b, Ly6G^-Ly6C^hi CD11b,GR-1,IL-4Rα CD11b,Ly6C^hi	10 different models (mice) 5 different tumor models (mice) EAE (mice)	[87] [65] [127]
TGFβ secretion	GR-1, CD115	MCA-26 colon carcinoma (mice)	[93]
IL-10 secretion	CD11b, GR-1 GR-1, CD115	4T1 breast carcinoma (mice) MCA-26 colon carcinoma (mice)	[107] [93]
Cysteine depletion	CD11b, GR-1	4T1 breast carcinoma (mice)	[131]
CD62L down-regulation	CD11b, GR-1	4T1 breast carcinoma (mice)	[133]
B7-H4, PD-L1 (B7-H1) expression	CD68 CD1a,HLA-DR	HCC (human) Ovarian cancer (human)	[136] [134, 135]

NSCLC, non-small cell lung carcinoma; RCC, renal cell carcinoma; EAE is Experimental Autoimmune Encephalomyelitis; HCC, hepatocellular carcinoma